Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

Fabian Dominik Mairinger; Claudia Vollbrecht; Elena Flom; Daniel Christian Christoph; Kurt-Werner Schmid; Jens Kollmeier; Helmut Hans Popper; Thomas Mairinger; Robert Fred Henry Walter

doi:10.18632/oncotarget.16398

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

Fabian Dominik Mairinger _, Claudia Vollbrecht, Elena Flom, Daniel Christian Christoph, Kurt-Werner Schmid, Jens Kollmeier, Helmut Hans Popper, Thomas Mairinger and Robert Fred Henry Walter

PDF | HTML | How to cite

Oncotarget. 2017; 8:37502-37510. https://doi.org/10.18632/oncotarget.16398

Metrics: PDF 1420 views | HTML 2329 views | ?

Abstract

Fabian Dominik Mairinger1, Claudia Vollbrecht2,3,4, Elena Flom1, Daniel Christian Christoph5, Kurt-Werner Schmid1, Jens Kollmeier6, Helmut Hans Popper7, Thomas Mairinger8 and Robert Fred Henry Walter1,9

1Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

2Institute of Pathology, Division of Molecular Pathology, Charité, Berlin, Germany

3German Cancer Consortium (DKTK), Germany

4German Cancer Research Center (DKFZ), Heidelberg, Germany

5Department of Medical Oncology, West German Cancer Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

6Department of Pneumology, Helios Klinikum Emil von Behring, Berlin, Germany

7Department of Pathology, Division of Molecular Lung- and Pleurapathology, Medical University of Graz, Graz, Austria

8Department of Pathology, Helios Klinikum Emil von Behring, Berlin, Germany

9Ruhrlandklinik, West German Lung Centre, University Hospital Essen, University of Duisburg-Essen, Essen, Germany

Correspondence to:

Fabian Dominik Mairinger, email: [email protected]

Keywords: pleural mesothelioma, pemetrexed, thymidylate synthethase, folylpolyglutamate synthase, personalized therapy

Received: October 12, 2016 Accepted: March 01, 2017 Published: March 21, 2017

ABSTRACT

Background: Malignant pleural mesothelioma (MPM) is a rare tumor linked to a dismal prognosis. Even the most effective chemotherapeutical regime of pemetrexed combined with cisplatin leads to a remission-rate of only about 40%. The reasons for the rather poor efficacy remain largely unknown.

Results: Phenotypes were significantly associated with progression (p=0.0279) and remission (p=0.0262). Cox-regression revealed significant associations between SLC19A1/TYMS-ratio (p=0.0076) as well as FPGS/TYMS-ratio (p=0.0026) and OS. For differentiation by risk-groups, COXPH identified a strong correlation (p=0.0008).

Methods: 56 MPM specimens from patients treated with pemetrexed were used for qPCR analysis. Phenotypes and risk groups were defined by their expression levels of members of the folic acid metabolism and correlated to survival and objective response.

Conclusion: Our results indicate that the balance between folic acid uptake, activation and metabolism plays a crucial role in response to pemetrexed-based chemotherapy and the prognosis of MPM patients. Implementing this marker profile in MPM stratification may help to individualize MPM-therapy more efficiently.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16398

Publication Alerts

Research Papers:

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma

Abstract